Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaporized Perfluorocarbon Inhalation in ARDS
NCT01391481Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2011
- Primary completion
- Apr 2013
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, randomised trial of perfluorocarbon liquid in acute respiratory distress syndrome (ARDS) and acute lung injury (ALI), sponsored by Chinese PLA General Hospital. Primary endpoints: Oxygenation index at 3 years and Respiratory mechanics at 3 years. Status: unknown.
02
Drugs
perfluorocarbon liquid
03
Conditions
acute respiratory distress syndrome (ARDS)acute lung injury (ALI)
Beyond the preview
Go deeper on NCT01391481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01391481.